Insights on NervGen Pharma’s Positive Phase 1b/2a Data for NVG-291 in Spinal Cord Injury

Daniel Mikol, MD, PhD, chief medical officer at NervGen Pharma, provided clinical perspective on recently announced positive findings from a phase 1b/2a trial testing NVG-291 as a treatment for spinal cord injury.:

Source: Neurology Read More

Previous PostFDA Accelerated Approval Open for FSHD Agent Del-Brax, With Newly Initiated Phase 3 Study to Confirm Efficacy
Next PostOnce-Nightly Oxybate Reduces Sleep-Related Eating, Samelisant Improves Excessive Daytime Sleepiness, Tirzepatide's Impact on OSA and Obesity

Insights on NervGen Pharma’s Positive Phase 1b/2a Data for NVG-291 in Spinal Cord Injury

Previous PostFDA Accelerated Approval Open for FSHD Agent Del-Brax, With Newly Initiated Phase 3 Study to Confirm Efficacy

Next PostOnce-Nightly Oxybate Reduces Sleep-Related Eating, Samelisant Improves Excessive Daytime Sleepiness, Tirzepatide's Impact on OSA and Obesity

Related Posts

<![CDATA[Sex Differences, Hormonal Influences, and Caregiving Burden in Women With Parkinson Disease]]>

<![CDATA[Highlights in Movement Disorders From the 2026 AMDAPP Conference: Erin Zinn, MSN, APRN-CNP, ANP-BC, CMRD]]>

<![CDATA[IVIG Demonstrates Improved Response Rates in Autoimmune Encephalitis Trial]]>

Categories